8-K: ZimVie Stockholders Approve ARCHIMED Acquisition

ZimVie Inc. stockholders have overwhelmingly approved the acquisition of the company by an affiliate of ARCHIMED, paving the way for the merger to close on October 20, 2025.

Summary

• ZimVie Inc. stockholders approved the Agreement and Plan of Merger with Zamboni Parent Inc. (an ARCHIMED affiliate) at a special meeting held on October 10, 2025.
• The Merger Agreement Proposal received 20,615,874 votes For, 29,686 Against, and 55,748 Abstained, with 0 Broker Non-Votes.
• This represents approximately 73.38% of the 28,210,715 shares outstanding and entitled to vote as of the September 2, 2025 record date.
• Stockholders also approved, on an advisory (non-binding) basis, the compensation for named executive officers related to the merger, with 16,997,513 For, 3,664,375 Against, and 39,420 Abstained.
• Upon completion, ZimVie will become a wholly-owned subsidiary of Parent, its common stock will be delisted from Nasdaq, and deregistered under the Securities Exchange Act of 1934.
• The parties now expect the merger to close on October 20, 2025.

Sentiment

Score: 8

Explanation: The overwhelming stockholder approval of the merger agreement provides a clear path to closing, offering certainty to shareholders. The acquisition by ARCHIMED, a specialized healthcare investment firm, suggests a strategic alignment for ZimVie's future as a private entity.

Positives

• Overwhelming stockholder approval of the merger agreement (20,615,874 votes For) provides certainty for the transaction.
• A clear path to merger completion is established, expected by October 20, 2025, which offers a defined exit for current shareholders.
• The advisory approval of executive compensation related to the merger indicates alignment on post-transaction incentives.

Negatives

• ZimVie common stock will be delisted from the Nasdaq Global Select Market and deregistered, ending its public trading status.
• The company will cease to be publicly held, removing investment opportunities in its standalone public entity.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Any or all of the various conditions to the consummation of the proposed transaction may not be satisfied or waived.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the definitive transaction agreement.
• The announcement or pendency of the proposed transaction may affect ZimVie's ability to attract, motivate, or retain key executives and employees.
• The proposed transaction may impact ZimVie's ability to maintain relationships with its customers, suppliers, and other business counterparties, or its operating results and business generally.
• Risks related to the proposed transaction diverting management's attention from ZimVie's ongoing business operations.
• The risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay.
• Other risks discussed in ZimVie's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025.

Future Outlook

The merger is expected to close on October 20, 2025, at which point ZimVie will become a privately held, wholly-owned subsidiary of Zamboni Parent Inc., an affiliate of ARCHIMED. The company's common stock will be delisted from Nasdaq and deregistered.

Management Comments

• ZimVie announced that its stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED.

Industry Context

ZimVie operates as a global life sciences leader in the dental implant market, offering products and solutions for dental tooth replacement and restoration. ARCHIMED is a leading investment firm focused exclusively on healthcare industries, with a specific interest in MedTech, aligning with ZimVie's core business. This acquisition represents a strategic move by ARCHIMED to expand its portfolio within the specialized healthcare sector.

Corporate Governance

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay, is identified as a forward-looking risk.

Stakeholder Impact

• Shareholders: Will receive consideration for their shares upon merger completion, ending their ownership in a publicly traded entity.
• Employees: Potential for changes in management, structure, or operations as ZimVie integrates into ARCHIMED's portfolio.
• Customers/Suppliers: Business continuity is expected, but potential for strategic shifts under new ownership.

Next Steps

• Completion of the merger, expected on October 20, 2025.
• ZimVie's common stock will be delisted from the Nasdaq Global Select Market.
• ZimVie's common stock will be deregistered under the Securities Exchange Act of 1934.

Key Dates

Keywords

ZimVie, ARCHIMED, merger, acquisition, stockholder vote, dental implants, life sciences, medical devices, delisting, corporate governance, ZIMV